Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of “Moderate Buy” by Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO) has received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $15.40.

ANRO has been the subject of a number of analyst reports. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research note on Friday, March 21st. HC Wainwright initiated coverage on shares of Alto Neuroscience in a report on Monday, April 7th. They issued a “buy” rating and a $10.00 price target on the stock.

Alto Neuroscience Trading Down 0.2 %

NYSE:ANRO opened at $2.25 on Tuesday. The firm has a 50-day simple moving average of $2.73 and a 200-day simple moving average of $4.53. Alto Neuroscience has a one year low of $1.60 and a one year high of $17.55. The firm has a market cap of $60.78 million, a P/E ratio of -0.88 and a beta of 2.16. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.09. Equities analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

Several institutional investors have recently added to or reduced their stakes in ANRO. Charles Schwab Investment Management Inc. increased its holdings in shares of Alto Neuroscience by 182.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 186,968 shares of the company’s stock valued at $2,139,000 after acquiring an additional 120,779 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Alto Neuroscience by 619.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after purchasing an additional 3,715 shares in the last quarter. State Street Corp increased its stake in Alto Neuroscience by 123.7% during the 3rd quarter. State Street Corp now owns 236,857 shares of the company’s stock valued at $2,710,000 after purchasing an additional 130,985 shares in the last quarter. Wellington Management Group LLP purchased a new position in shares of Alto Neuroscience in the third quarter worth $694,000. Finally, Jane Street Group LLC acquired a new stake in shares of Alto Neuroscience during the third quarter worth $124,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.